Food and Drug Administration, HHS.
The Food and Drug Administration (FDA) is announcing the availability of guidance entitled “M4 Organization of the Common Technical Document for the Registration of Pharmaceuticals for Human Use” (M4 CTD). The guidance was developed under the auspices of the International Conference on Harmonisation of Start Printed Page 52635Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). The guidance, which is being made available simultaneously in four parts (general organization, quality, safety, and efficacy), describes a harmonized format for new product applications (including applications for biotechnology-derived products) for submission to the regulatory authorities in the three ICH regions. The M4 CTD is intended to reduce the time and resources used to compile applications, ease the preparation of electronic submissions, facilitate regulatory reviews and communication with the applicant, and simplify the exchange of regulatory information among regulatory authorities.
Submit written or electronic comments on agency guidances at any time.
Submit written requests for single copies of the guidance to the Division of Drug Information (HFD-240), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857; or the Office of Communication, Training, and Manufacturers Assistance (HFM-40), Center for Biologics Evaluation and Research (CBER), 1401 Rockville Pike, Rockville, MD 20852-1448, 301-827-3844, FAX 888-CBERFAX. Send two self-addressed adhesive labels to assist the office in processing your requests. Submit written comments on the guidance to the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to http://www.fda.gov/dockets/ecomments. Requests and comments should be identified with the docket number found in brackets in the heading of this document. See the SUPPLEMENTARY INFORMATION section of this document for electronic access to the guidance.Start Further Info
FOR FURTHER INFORMATION CONTACT:
Regarding the guidance: For the safety (nonclinical) components: Joseph J. DeGeorge, Center for Drug Evaluation and Research (HFD-24), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-5476, or David Green, Center for Biologics Evaluation and Research (HFM-579), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-827-5349.
For the quality components: Charles P. Hoiberg, Center for Drug Evaluation and Research (HFD-810), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-2570, or Neil Goldman, Center for Biologics Evaluation and Research (HFM-20), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-827-0372.
For the efficacy (clinical) sections: Robert Temple, Center for Drug Evaluation and Research (HFD-40), Food and Drug Administration, 9201 Corporate Blvd., Rockville, MD 20850, 301-594-6758, or Lou Marzella, Center for Biologics Evaluation and Research (HFM-582), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301-827-5080.
Regarding the ICH: Janet J. Showalter, Office of International Programs (HFG-1), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-0864.End Further Info End Preamble Start Supplemental Information
In recent years, many important initiatives have been undertaken by regulatory authorities and industry associations to promote international harmonization of regulatory requirements. FDA has participated in many meetings designed to enhance harmonization and is committed to seeking scientifically based harmonized technical procedures for pharmaceutical development. One of the goals of harmonization is to identify and, when possible, reduce differences in technical requirements.
ICH was organized to provide an opportunity for harmonization initiatives to be developed with input from both regulatory and industry representatives. ICH is concerned with harmonization among three regions: The European Union, Japan, and the United States. The six ICH sponsors are the European Commission; the European Federation of Pharmaceutical Industries Associations; the Japanese Ministry of Health, Labor, and Welfare; the Japanese Pharmaceutical Manufacturers Association; the Centers for Drug Evaluation and Research and Biologics Evaluation and Research, FDA; and the Pharmaceutical Research and Manufacturers of America. The ICH Secretariat, which coordinates the preparation of documentation, is provided by the International Federation of Pharmaceutical Manufacturers Associations (IFPMA).
The ICH Steering Committee includes representatives from each of the ICH sponsors and the IFPMA, as well as observers from the World Health Organization, the Canadian Therapeutics Products Programme, and the European Free Trade Area.
The ICH process has achieved significant harmonization of the technical requirements for the approval of pharmaceuticals for human use in the three ICH regions. However, until recently, the format of the technical documentation in an application to market a new medicinal product in the three ICH regions had not been considered in the ICH process although there are substantial differences in the organization of product applications in different parts of the world. ICH, therefore, convened three Expert Working Groups (with expertise in quality, safety, and efficacy of human drug and therapeutic biological products) to develop harmonized guidance for the format of sections of a marketing application for a new medicinal product. This effort is called the “common technical document.” The resulting ICH guidance M4 CTD describes an acceptable format for applications for new human pharmaceuticals that (supplemented with regional particulars) can be used for submission to the regulatory authorities in each of the three ICH regions. The organization and format guidance provided in the M4 CTD is intended to be used together with information about the content of an application, which is provided in other ICH and FDA guidances.
In the Federal Register of February 11, 2000 (65 FR 7024), the agency announced the availability of initial components of the draft CTD guidance and requested public comment. Comments from that announcement were considered in developing a draft tripartite guidance, which was made available in the Federal Register of August 24, 2000 (65 FR 51621). The notice for the draft guidance gave interested persons an opportunity to submit comments by September 30, 2000.
To facilitate the process of making ICH guidances available to the public, the agency has changed its procedures for publishing ICH guidances. Since April 2000, we no longer include the text of ICH guidances in the Federal Register. Instead, we publish a notice in the Federal Register announcing the availability of an ICH guidance. The ICH guidance is placed in the docket and can be obtained through regular agency sources (see the ADDRESSES section of this document). Draft guidances are left in their original ICH format. Final guidances are reformatted and edited to Start Printed Page 52636conform to the good guidance practices (GGP) style before publication.
After consideration of the comments received and revisions to the guidance, a final draft of the guidance was submitted to the ICH Steering Committee and endorsed by the three participating regulatory agencies in November 2000.
In accordance with FDA's GGP regulation (21 CFR 10.115), ICH guidance documents are now being called guidances, rather than guidelines.
II. The Common Technical Document
The M4 CTD guidance describes a harmonized format for new product applications (including applications for biotechnology-derived products) for submission to the regulatory authorities in the three ICH regions. The common technical document is intended to reduce the time and resources used to compile applications, ease the preparation of electronic submissions, facilitate regulatory reviews and communication with the applicant, and simplify the exchange of regulatory information among regulatory authorities.
The guidance addresses the organization of information presented in new product applications. With appropriate modifications, the guidance can also be applied to abbreviated or other applications. The guidance is not intended to indicate what studies should be included, but indicates an appropriate format for data that are submitted.
The common technical document should be viewed as the common part of a submission for new products, presented in a modular fashion with summaries and tables. It is intended that one of the modules (module I) in the common technical document be reserved as a region-specific module, and thus will not be harmonized.
The common technical document modular structure is envisioned as shown in the graphic at the end of this notice and the following table of contents for the document:
Module 1: Administrative Information and Prescribing Information
1.1 Table of Contents of the Submission Including Module 1
1.2 Documents Specific to Each Region (for example, application forms, prescribing information)
Module 2: Common Technical Document Summaries
2.1 CTD Table of Contents
2.2 CTD Introduction
2.3 Quality Overall Summary
2.4 Nonclinical Overview
2.5 Clinical Overview
2.6 Nonclinical Written and Tabulated Summaries
2.7 Clinical Summary
Biopharmaceutics and Associated Analytical Methods
Clinical Pharmacology Studies
Synopses of Individual Studies
Module 3: Quality
3.1 Module 3 Table of Contents
3.2 Body of Data
3.3 Literature References
Module 4: Nonclinical Study Reports
4.1 Module 4 Table of Contents
4.2 Study Reports
4.3 Literature References
Module 5: Clinical Study Reports
5.1 Module 5 Table of Contents
5.2 Tabular Listing of All Clinical Studies
5.3 Clinical Study Reports
5.4 Literature References
The guidance being made available with this notice is the product of the ICH Common Technical Document Expert Working Groups for Quality, Safety, and Efficacy. To facilitate the handling of the guidance, it is being made available in four parts: (1) A description of the organization of the M4 CTD; (2) the Quality section; (3) the Safety, or nonclinical, section; and (4) the Efficacy, or clinical, section.
It should be noted that, as part of the ICH process, additional guidance is being developed to facilitate the submission of CTD applications using standardized electronic (computer) formats. This “electronic CTD,” or “E-CTD,” is an ultimate aim of current harmonization efforts in this area. There may be some modifications in the CTD format to facilitate the preparation and utility of the E-CTD, although substantive modifications are not anticipated.
This guidance represents the agency's current thinking on the organization and format of a common application for new products (i.e., the common technical document). It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statutes and regulations.
Interested persons may, at any time, submit to the Dockets Management Branch (address above) written comments regarding the guidance. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. The guidance and received comments may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.
IV. Electronic AccessStart Printed Page 52637 Start Signature
Dated: October 9, 2001.
Margaret M. Dotzel,
Associate Commissioner for Policy.
[FR Doc. 01-25921 Filed 10-15-01; 8:45 am]
BILLING CODE 4160-01-C